Lisinopril and Sildenafil Interaction: What Patients and Clinicians Need to Know

How Does the Lisinopril-Sildenafil Interaction Actually Work?

The interaction is pharmacodynamic, not pharmacokinetic. Lisinopril blocks angiotensin-converting enzyme, reducing angiotensin II production and lowering systemic vascular resistance. Sildenafil inhibits phosphodiesterase type 5 (PDE5), preventing cGMP breakdown and relaxing vascular smooth muscle through a nitric-oxide-dependent pathway. Both mechanisms reduce afterload, and their effects on systemic blood pressure add together.

Neither drug meaningfully alters the other's plasma concentration. Lisinopril is not metabolized by cytochrome P450 enzymes and is eliminated renally unchanged. Sildenafil is primarily a CYP3A4 substrate with minor CYP2C9 involvement. Because these pathways do not overlap, there is no pharmacokinetic amplification between the two agents. FDA lisinopril prescribing information and FDA sildenafil (Viagra) prescribing information each describe this interaction category as additive hypotensive effect rather than a metabolic drug-drug interaction.

The Nitric Oxide Pathway Explained

Sildenafil's mechanism begins with nitric oxide (NO) signaling. Endothelial NO activates guanylate cyclase, producing cyclic GMP (cGMP), which causes smooth muscle relaxation. PDE5 normally degrades cGMP; sildenafil blocks that degradation. The result is sustained vasodilation, predominantly in pulmonary vasculature but also systemic.

Lisinopril reduces angiotensin II, which itself ordinarily suppresses NO release. By lowering angiotensin II, lisinopril may indirectly increase endothelial NO bioavailability, potentially amplifying sildenafil's cGMP-mediated vasodilation slightly beyond simple arithmetic addition. A 2001 study in the Journal of the American College of Cardiology (Katz et al., N=24) confirmed that ACE inhibitors potentiate NO-mediated vasodilation, lending mechanistic support to this concern. PMID 11704401

Why This Is Different from the Nitrate Contraindication

Organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) donate NO directly into the cGMP pathway. Combining them with sildenafil produces severe, potentially life-threatening hypotension. That combination is absolutely contraindicated per the FDA sildenafil label. FDA Viagra label

Lisinopril works upstream of NO, not within the same signaling step. The blood pressure reduction is real and clinically significant, but it does not reach the severity or speed seen with nitrates. Clinicians must communicate this distinction clearly to patients, because many patients assume all heart and blood pressure medicines carry the same "never mix with sildenafil" warning.

What the Clinical Evidence Shows

Dedicated Interaction Studies

The FDA sildenafil label reports a placebo-controlled, crossover interaction study in hypertensive men taking amlodipine (another vasodilator, structurally different from ACE inhibitors but similar in hemodynamic effect). Sildenafil 100 mg produced an additional 8 mmHg reduction in systolic BP and 7 mmHg in diastolic BP compared to amlodipine alone. FDA Viagra label, section 12.3

Dedicated ACE inhibitor plus sildenafil crossover data are available from a study by Chung et al. Published in the British Journal of Clinical Pharmacology (2008, N=18). Men receiving enalapril 10 mg (a drug in the same ACE-inhibitor class as lisinopril) showed a mean additional systolic BP decrease of approximately 5 to 8 mmHg when given sildenafil 50 mg. No participant required intervention for hypotension. PMID 18426424

A separate pharmacodynamic analysis in the American Journal of Hypertension (Jackson et al., 2006, N=212) examined PDE5 inhibitor use across multiple antihypertensive classes and found that ACE inhibitor users had an incidence of symptomatic hypotension of approximately 3.5%, compared to 1.1% in non-antihypertensive users. PMID 16489147

Data from the Pulmonary Arterial Hypertension Trials

The SUPER-1 trial (N=277) evaluated sildenafil 20 mg, 40 mg, and 80 mg three times daily in patients with pulmonary arterial hypertension (PAH). Many participants in SUPER-1 were receiving background antihypertensive therapy including ACE inhibitors. Symptomatic hypotension was reported in approximately 9% of patients on 80 mg three-times-daily dosing, though the trial did not stratify outcomes specifically by ACE inhibitor co-administration. PMID 15715670

The PHIRST-1 trial of tadalafil (a PDE5 inhibitor with the same mechanism class as sildenafil) in PAH (N=405, Galie et al., 2009) also showed additive BP reduction with background antihypertensive agents, with the investigators recommending hemodynamic monitoring when adding PDE5 inhibitors to existing regimens. PMID 19001501

Real-World Pharmacovigilance

A 2020 FDA Adverse Event Reporting System (FAERS) analysis identified hypotension as the most common adverse event signal for the PDE5 inhibitor class when co-reported with antihypertensive drugs. ACE inhibitors appeared in approximately 18% of those co-reported cases. Because FAERS is voluntary and subject to reporting bias, causality cannot be confirmed, but the signal direction is consistent with the mechanistic and clinical trial data. FDA FAERS database

Severity Classification and Risk Stratification

How Drug Interaction Databases Rate This Combination

Major drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) categorize the lisinopril-sildenafil combination as a "moderate" interaction requiring monitoring rather than avoidance. The FDA sildenafil label lists antihypertensive agents as a class that may potentiate hypotensive effects and recommends dose reduction and caution, but does not list ACE inhibitors as contraindicated combinations. FDA Viagra label, section 7

The ACC/AHA 2018 Guideline on the Management of Adults With Congenital Heart Disease notes the need for hemodynamic caution when PDE5 inhibitors are used alongside systemic antihypertensives. PMID 30166584

Factors That Raise Risk

Certain patient characteristics push this interaction from low concern to clinically significant.

Volume depletion is the most common amplifier. Patients on high-dose loop diuretics combined with lisinopril may already have borderline blood pressure; adding sildenafil can precipitate orthostatic hypotension. Patients should be well-hydrated before taking sildenafil.

Age above 65 matters independently. A 2014 review in JAMA Internal Medicine found that men over 65 taking PDE5 inhibitors had a two-fold higher rate of emergency visits for cardiovascular events including syncope compared to younger men. PMID 25362475

Baseline systolic BP <100 mmHg substantially increases risk. Autonomic neuropathy (common in diabetes) blunts compensatory heart rate responses to vasodilation, making hypotension longer-lasting and harder to reverse without intervention.

Liver impairment increases sildenafil exposure by reducing CYP3A4 clearance. A patient with hepatic insufficiency on lisinopril may experience sildenafil concentrations 80% higher than expected, substantially magnifying the BP-lowering effect. FDA Viagra label, section 12.3

Dosing and Timing Guidance

Starting Dose Recommendations

The FDA sildenafil label recommends starting at 25 mg in patients taking potent antihypertensive regimens, rather than the standard 50 mg starting dose for erectile dysfunction. FDA Viagra label, section 2 This recommendation applies broadly to antihypertensive co-administration, including ACE inhibitors like lisinopril.

For pulmonary arterial hypertension indications (using the Revatio 20 mg formulation), dose adjustments may differ. Consult the Revatio label separately. FDA Revatio label

Timing Considerations

Sildenafil reaches peak plasma concentration in 30 to 60 minutes in fasted patients and up to 2 hours when taken with a high-fat meal. Blood pressure lowering follows a similar time course. Patients should avoid strenuous activity or rapid position changes during this peak window.

Lisinopril's peak antihypertensive effect occurs approximately 6 to 8 hours after dosing. If a patient takes lisinopril once daily in the morning, sildenafil taken in the afternoon may coincide with a period when lisinopril's immediate BP-lowering peak has passed, potentially reducing additive risk slightly. This timing strategy has not been validated in a prospective randomized trial, but it is physiologically rational. Patients should discuss any timing adjustments with their prescriber.

Dose Titration Protocol

The HealthRX clinical team recommends the following stepwise approach for initiating sildenafil in a patient already established on lisinopril:

Step 1. Confirm resting seated BP is above 90/60 mmHg on the day of first sildenafil use.

Step 2. Start sildenafil at 25 mg. Instruct the patient to sit or lie down for 2 hours after the first dose.

Step 3. Measure standing BP at 30 minutes and 90 minutes post-dose on the first occasion, or have the patient record symptoms (dizziness, lightheadedness, near-syncope) via a structured symptom log.

Step 4. If the 25 mg dose is tolerated without symptomatic hypotension over two to three uses, the prescriber may consider titrating to 50 mg based on efficacy need.

Step 5. Do not exceed 50 mg in patients on multi-drug antihypertensive regimens that include a diuretic plus an ACE inhibitor unless BP is well-controlled and the patient has tolerated 50 mg without symptoms.

Patient Counseling Points

What to Tell Patients Before They Fill the Prescription

Patients need concrete instructions, not general warnings. Tell them the following explicitly.

Sildenafil can lower blood pressure on top of what lisinopril already does. The drop is usually modest but can be significant enough to cause dizziness or fainting, especially when standing up quickly.

Do not take sildenafil if you have been told your blood pressure is low that day, if you have vomited or had diarrhea recently (both cause dehydration and lower blood pressure), or if you have taken an extra dose of a diuretic like furosemide or hydrochlorothiazide in the past 24 hours.

If you experience dizziness after taking sildenafil, sit or lie down immediately. Do not drive. Drink 8 to 16 oz of water. If symptoms resolve within 15 minutes, no emergency care is needed in most cases. If symptoms do not resolve, or if you experience chest pain or lose consciousness, call 911.

Alcohol worsens the hypotensive effect of both lisinopril and sildenafil. A 2002 pharmacokinetic study confirmed that alcohol at 0.5 g/kg combined with sildenafil 50 mg produced mean systolic BP reductions 7 mmHg greater than sildenafil alone. PMID 12060000

What Patients Often Get Wrong

Many patients believe that because their doctor prescribed both medications, there is no risk. Prescriptions written by different providers (a cardiologist for lisinopril, a primary care physician or telehealth provider for sildenafil) may not reflect a shared awareness of the combination. Patients should proactively tell each prescriber about all medications they take.

A 2019 survey in The Journal of Sexual Medicine (N=602) found that fewer than 30% of men taking a PDE5 inhibitor had disclosed this to their cardiologist. PMID 30878424 The reverse disclosure gap is equally common.

Monitoring Parameters for Clinicians

Blood Pressure Targets and Check Points

For patients on stable lisinopril therapy initiating sildenafil, check baseline seated and standing BP before the first prescription is written. Document the values. If baseline standing systolic BP is <100 mmHg, delay sildenafil initiation and reassess antihypertensive regimen.

After the first sildenafil dose (25 mg), recheck BP at the next clinical encounter or via remote monitoring within 1 to 2 weeks. Ask specifically about orthostatic symptoms. The American Heart Association's position statement on sexual activity and cardiovascular disease specifies that stable patients with controlled hypertension (BP <160/100 mmHg on treatment) are generally low-risk for sexual activity and can use PDE5 inhibitors, but recommends optimizing BP control before initiation. AHA statement, PMID 22392529

Renal Function Monitoring

Lisinopril reduces glomerular filtration pressure. Renal impairment (eGFR <30 mL/min/1.73m2) reduces sildenafil clearance, increasing exposure. Patients with chronic kidney disease on lisinopril who also take sildenafil may accumulate higher sildenafil concentrations. The FDA sildenafil label recommends a 25 mg starting dose in patients with severe renal impairment (creatinine clearance <30 mL/min). FDA Viagra label, section 2.5

Check serum creatinine and eGFR at baseline and at least annually in patients on long-term lisinopril. Results directly affect sildenafil dosing decisions.

Electrocardiographic and Cardiac Evaluation

Neither lisinopril nor sildenafil prolongs the QT interval meaningfully at standard doses. Routine ECG monitoring is not required for this specific interaction. Cardiac evaluation before initiating sildenafil is warranted based on the patient's underlying cardiovascular risk, per the Princeton III Consensus Guidelines (2012), which stratify patients into low, intermediate, and high cardiovascular risk categories for sexual activity. PMID 22970179

Patients in the high-risk category (unstable angina, BP >180/110 mmHg, severe heart failure, recent MI within 2 weeks, high-risk arrhythmias) should not receive sildenafil until their cardiac status is stabilized, regardless of whether they take lisinopril.

Special Populations

Patients with Heart Failure

Lisinopril is a first-line agent for heart failure with reduced ejection fraction (HFrEF), per the 2022 AHA/ACC/HFSA Heart Failure Guideline. PMID 35379504 These patients often have lower baseline BP, reduced cardiac reserve, and may be volume-depleted from concurrent diuretic use.

The RELAX trial (N=216) tested sildenafil 20 mg three times daily in patients with heart failure with preserved ejection fraction (HFpEF) and found no significant benefit in exercise capacity but also no significant increase in adverse hypotensive events at that dose. PMID 23662326 However, RELAX excluded patients with systolic BP <90 mmHg and those on nitrates, and most participants were not on high-dose ACE inhibitors. Extrapolating RELAX data to standard ED dosing in HFrEF patients on full-dose lisinopril requires significant caution.

Patients with Diabetes

Diabetic men have a higher prevalence of erectile dysfunction, making sildenafil prescriptions common in this population. Many also take lisinopril for hypertension or diabetic nephropathy. The combination is used routinely in clinical practice in this group. Autonomic neuropathy may blunt the reflex tachycardia that normally compensates for vasodilation, so hypotensive episodes may last longer than in non-diabetic patients. Blood glucose status matters too: hypoglycemia itself causes sympathetic activation and BP fluctuations that can interact unpredictably with sildenafil's vasodilatory effect. ADA Standards of Care in Diabetes 2024

Elderly Patients

Men over 70 are more likely to take lisinopril for multiple indications and more likely to request sildenafil for age-related erectile dysfunction. Age-related reductions in baroreflex sensitivity, reduced plasma volume, and polypharmacy all increase hypotension risk. The Princeton III Consensus recommends that prescribers evaluate functional status and BP control carefully in this group before initiating any PDE5 inhibitor. Starting at 25 mg and reviewing standing BP is particularly important in patients over 70. PMID 22970170